Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.
OCR for page 199
Scaling Up Treatment for the Global AIDS Pandemic: Challenges and Opportunities Appendix A Information Gathering Workshop Agenda Committee on Examining the Probable Consequences of Alternative Patterns of Widespread Antiretroviral Drug Use in Resource-Constrained Settings Tuesday, January 27, 2004 Room 100, Keck Building 500 5th Street, NW Washington, DC 2001 8:00-8:20 Welcome, Introduction of Committee, and Statement of Charge Dr. James Curran and Dr. Haile Debas Committee Cochairs The Opportunity 8:20-8:45 The Challenge of HIV/AIDS in 2004 and the WHO 3 × 5 Program Dr. Jim Kim Advisor to the Director-General World Health Organization Geneva, Switzerland
OCR for page 200
Scaling Up Treatment for the Global AIDS Pandemic: Challenges and Opportunities 8:45-9:10 The Global Funds’ Lessons Learned Regarding ARV Drug Scale-up in Resource-Constrained Settings Dr. Bernhard Schwartlander Director Strategic Information and Measurement Global Fund to Fight AIDS, TB, and Malaria Geneva, Switzerland 9:10-9:35 The U.S. Emergency Plan for Antiretroviral Scale-up: The Latest Programmatic Developments Dr. Joe O’Neil Deputy Coordinator Office of the Global AIDS Coordinator Department of State Washington, DC 9:35-9:55 General Discussion 9:55-10:15 BREAK Antecedents 10:15-10:40 Durability of ARV Therapy: U.S. Experience and Its Implications for Resource-Constrained Settings Dr. Robert Redfield Cofounder and Director of Clinical Care and Research Division, Institute of Human Virology University of Maryland Baltimore, MD 10:40-11:05 A U.S. Clinical Perspective on the Implications of ARV Resistance for Resource-Constrained Settings Dr. Steven Deeks Associate Clinical Professor of Clinical Medicine University of California, San Francisco San Francisco, CA 11:05-11:30 Lessons Learned from the Scale-up of ARV Treatment in Brazil Dr. Mauro Schechter Professor of Infectious Diseases Universidade Federal do Rio de Janeiro, Brazil
OCR for page 201
Scaling Up Treatment for the Global AIDS Pandemic: Challenges and Opportunities 11:30-11:55 Lessons Learned from the Use of ARVs in Very Low-Resource Settings: The Haiti Experience Dr. Daniel Fitzgerald Groupe Haitien d’Étude du Sarcome de Kaposi et des infections Opportunistes (GHESKIO) Port-au-Prince, Haiti, and Division of International Medicine and Infectious Diseases Cornell University Medical College New York, NY 11:55-12:20 MSF Perspectives on ARV Administration: Experiences from 20 countries and 10,000 Patients Ms. Rachel Cohen U.S. Director, Campaign for Access to Essential Medicines Médecins sans Frontières New York, NY 12:20-12:50 General Discussion 12:50-1:50 LUNCH Clinical Principles for ARV Scale-up Programs 1:50-2:15 The 2003 WHO Guidelines for ARV Use: Perspectives from a User Dr. John Idoko Professor Jos University Teaching Hospital Jos, Nigeria 2:15-2:40 MTCT-Plus Initiative: Perspectives from a Multicountry Comprehensive HIV Care and Treatment Program Dr. Wafaa El-Sadr Professor Mailman School of Public Health Columbia University and Harlem Hospital New York, NY
OCR for page 202
Scaling Up Treatment for the Global AIDS Pandemic: Challenges and Opportunities 2:40-3:05 The Role of the Laboratory in Managing ARV Care in a Country with Highly Limited Resources Dr. Brooks Jackson Baxley Professor and Director of Pathology Johns Hopkins University School of Medicine Baltimore, MD 3:05-3:30 The Social and Behavioral Dimensions of Adherence: Implications for Patient Education Dr. Carla Makhlouf Obermeyer Scientist Department of HIV/AIDS World Health Organization Geneva, Switzerland 3:30-3:50 General Discussion 3:50-4:10 BREAK 4:10-4:35 Preventing Mother-to-Child Transmission: Issues of Therapy and Resistance Dr. Lynne Mofenson Pediatric, Adolescent and Maternal AIDS Branch Center for Research for Mothers and Children National Institute of Child Health and Human Development National Institutes of Health Bethesda, MD 4:35-5:00 Pediatric Considerations for ARV Programs in Resource-Constrained Settings Dr. Mark Kline Chief, Retrovirology Clinic Professor of Pediatrics Director, Baylor International Pediatric AIDS Initiative Baylor College of Medicine/Texas Children’s Hospital Houston, TX
OCR for page 203
Scaling Up Treatment for the Global AIDS Pandemic: Challenges and Opportunities 5:00-5:25 The Integration of Counseling, Prevention, and ARV Programs Dr. Sam Dooley Division of HIV/AIDS Prevention Centers for Disease Control and Prevention Atlanta, GA 5:25-6:00 Wrap-up Comments and Discussion Wednesday, January 28, 2004 Management Principles for Scale-up of ARV Programs 8:00-8:05 Opening Comments Dr. James Curran and Dr. Haile Debas Committee Cochairs 8:05-8:30 Principles of Design and Scale-up for National Clinical Care Programs and Applications to the WHO 3 × 5 Targets Dr. M. Rashad Massoud Vice President and Director Quality and Performance Institute University Research Co., LLC Bethesda, MD 8:30-8:55 An Overview of Health Care Manpower, Health Care Infrastructure, and Economics in Select Resource-Poor Countries Mr. Mead Over Lead Economist Development Research Group World Bank Washington, DC 8:55-9:20 The Role of Community Mobilization in the Scale-up of ARV programs Ms. Emi MacLean Médecins sans Frontières New York, NY
OCR for page 204
Scaling Up Treatment for the Global AIDS Pandemic: Challenges and Opportunities 9:20-9:45 Distribution of ARVs: Issues of Security, Logistics, and Quality Ms. Yasmin Chandani HIV/AIDS Advisor for DELIVER John Snow, Inc. Arlington, VA 9:45-10:10 Large Scale Training for ARV Providers: Observations from the United States Dr. John McNeil Chief, Infectious Diseases Howard University PI, National Minority AIDS Education and Training Center Washington, DC 10:10-10:30 General Discussion 10:30-10:50 BREAK 10:50-11:15 Perspectives on Purchasing First and Second Line ARVs Ms. Lynn Margherio Executive Vice President The Clinton Foundation HIV/AIDS Initiative 11:15-11:40 Delivering ARVs: The Economic Consequences of Resistance Dr. Stefano Bertozzi Director Economics and Policy Center of Research on Health Systems National Institute of Public Health Cuernavaca, Mexico 11:40-12:00 General Discussion 12:00-1:00 LUNCH
OCR for page 205
Scaling Up Treatment for the Global AIDS Pandemic: Challenges and Opportunities The Path Forward 1:00-1:25 Assessing Readiness for ARV Program Implementation Dr. Eric Goosby Chief Executive Officer Pangea Global AIDS Foundation San Francisco, CA 1:25-1:50 Specific Questions for Operations Research in the Scale-up of ARV Treatment Programs in Low-Resource Settings Dr. Tom Quinn Professor of Medicine Johns Hopkins University School of Medicine Baltimore, MD 1:50-2:15 The Role of Statistical Prediction Methods for Managing ARV Scale-up Programs Dr. Victor De Gruttola Professor of Biostatistics Harvard School of Public Health Boston, MA 2:15-2:40 Ethical Issues in the Scale-up of ARV Programs in Resource-Poor Settings Ms. Angela Wasunna Lawyer/Bioethicist Associate for International Programs The Hastings Center Garrison, NY 2:40-3:05 Discussion 3:05-3:30 BREAK 3:30-3:55 Information Management Considerations in Managing ARV Programs Mr. Ronaldo Lima International AIDS Vaccine Initiative New York, New York
OCR for page 206
Scaling Up Treatment for the Global AIDS Pandemic: Challenges and Opportunities 3:55-4:20 ARV Resistance: Epidemiologic Implications and Public Health Surveillance Dr. Diane Bennett World Health Organization Geneva, Switzerland 4:20-4:45 Monitoring and Evaluation for ARV Programs in Resource-Poor Settings Dr. Paul DeLay UNAIDS Geneva, Switzerland 4:45-5:10 The South African Plan for ARV Scale-up Dr. Tony Mbewu, Executive Director Medical Research Council of South Africa Capetown, South Africa 5:10-6:00 Discussion and Wrap-up
Representative terms from entire chapter: